Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Tag: GAVI

The € 7.4 billion for Covid-19 product and vaccine development needs...

Ellen 't Hoen - May 5, 2020

Recent Posts

The Waiver that Wasn’t: Is the pharma lobby responsible?
TRIPS, technology transfer and access to pandemic countermeasures: What the WHO Pandemic Treaty must do
Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert Group on the Pandemic Treaty published by BMJ Global Health
WTO Covid-19 TRIPS Decision: Some observations

Posts by Subject

Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi essential medicines list European Union evergreening Fair Pricing Gilead Hepatitis C IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs pandemic treaty Patents PrEP R&D remdesivir Sofosbuvir SPC The Netherlands transparency TRIPS Council TRIPS flexibilities TRIPS Waiver vaccines WHO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

This work is licensed under Creative Commons.